Home > Boards > US Listed > Biotechs > Verastem (VSTM)

VSTM does not look like a good short

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
jimmy667 Member Profile
 
Followed By 32
Posts 3,010
Boards Moderated 0
Alias Born 10/20/15
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:29:18 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 7/3/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 5:12:40 PM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on... Business Wire - 6/21/2019 7:00:00 AM
Verastem Oncology Announces Leadership Changes Business Wire - 6/20/2019 7:00:00 AM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:22:02 PM
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference Business Wire - 5/16/2019 7:00:00 AM
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study Business Wire - 5/15/2019 5:16:00 PM
Verastem Oncology Reports First Quarter 2019 Financial Results Business Wire - 5/9/2019 4:05:00 PM
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 Business Wire - 5/2/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 4:22:15 PM
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility Business Wire - 4/23/2019 4:05:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/8/2019 4:13:23 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 4/4/2019 4:05:00 PM
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire - 4/2/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 4:14:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/18/2019 6:10:17 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/12/2019 4:28:34 PM
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments Business Wire - 3/12/2019 4:08:00 PM
Verastem Oncology to Present at Upcoming Investor Conferences Business Wire - 3/12/2019 7:00:00 AM
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Mali... Business Wire - 3/7/2019 5:01:00 PM
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progresse... Business Wire - 3/4/2019 7:00:00 AM
jimmy667   Sunday, 05/19/19 11:45:23 AM
Re: stockguard post# 357
Post # of 411 
VSTM does not look like a good short play. It has $250 million or so cash with a market cap of only $113 million. It looks to be priced below current liquidation value because of large short interest at 25% of float. However before last report short interest was 36%. One would think the the remaining shorts will start buying to cover at these prices. VSTM has an attractive credit line AND an approved drug. The label black box AEs are being shown to be managed by dosing in the new data from the study. Plus the ongoing trials will likely expand the indications to new indications. It may not be the rocket ship bio trade some look for but downside risk is now fully priced in and upside potential is not. If the AEs can be managed and the ongoing trials expand the indications this could be an attractive BO target or attract favorable partnerships. Otherwise it could just slowly climb as the drug becomes more accepted by Oncologists. But I see little risk of a major slide as with most Bios as trial fail or stock offerings are announced. Looks to be a low risk play for the clinical trials as a drug is much easier to gain approval for a new indication once approved for another.
I am accumulating for a long term hold.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist